S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:CGIX

Cancer Genetics Stock Forecast, Price & News

$3.18
+0.02 (+0.63 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.05
Now: $3.18
$3.29
50-Day Range
$2.44
MA: $2.78
$3.42
52-Week Range
$1.92
Now: $3.18
$10.39
Volume174,265 shs
Average Volume519,774 shs
Market Capitalization$13.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.79
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.
Cancer Genetics logo

MarketRank

Overall MarketRank

0.77 out of 5 stars

Medical Sector

988th out of 1,558 stocks

Medical Laboratories Industry

21st out of 30 stocks

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGIX
CUSIPN/A
Phone201-528-9200
Employees110

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.30 million
Cash Flow$0.11 per share
Book Value$3.52 per share

Profitability

Net Income$-6,710,000.00

Miscellaneous

Market Cap$13.01 million
Next Earnings Date6/7/2021 (Estimated)
OptionableOptionable
$3.18
+0.02 (+0.63 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CGIX News and Ratings via Email

Sign-up to receive the latest news and ratings for CGIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions

How has Cancer Genetics' stock price been impacted by COVID-19?

Cancer Genetics' stock was trading at $3.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CGIX shares have decreased by 11.4% and is now trading at $3.18.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Cancer Genetics?

Wall Street analysts have given Cancer Genetics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cancer Genetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cancer Genetics' next earnings date?

Cancer Genetics is scheduled to release its next quarterly earnings announcement on Monday, June 7th 2021.
View our earnings forecast for Cancer Genetics
.

How were Cancer Genetics' earnings last quarter?

Cancer Genetics, Inc. (NASDAQ:CGIX) issued its quarterly earnings data on Thursday, November, 12th. The medical research company reported ($0.58) earnings per share for the quarter. The medical research company had revenue of $1.57 million for the quarter. Cancer Genetics had a negative return on equity of 76.14% and a negative net margin of 69.90%.
View Cancer Genetics' earnings history
.

Are investors shorting Cancer Genetics?

Cancer Genetics saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 28,600 shares, an increase of 78.8% from the December 15th total of 16,000 shares. Based on an average daily trading volume, of 359,300 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.8% of the company's stock are short sold.
View Cancer Genetics' Short Interest
.

Who are some of Cancer Genetics' key competitors?

What other stocks do shareholders of Cancer Genetics own?

Who are Cancer Genetics' key executives?

Cancer Genetics' management team includes the following people:
  • Mr. John A. Roberts M.B.A., MBA, Pres, CEO, Principal Financial Officer & Principal Accounting Officer (Age 61, Pay $269.03k)
  • Dr. Ralf Brandt, Pres of Discovery & Early Devel. Services (Age 53, Pay $439.47k)
  • Mr. Michael Brian McCartney M.B.A., Chief Commercial Officer (Age 55)
  • Mr. William Lansing Finger, Exec. VP of Precision Medicine & Biopharma Solutions (Age 50)
  • Dr. Lan Wang, Medical Director of New Jersey Reference Laboratory & Consultant

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?

Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $3.18.

How big of a company is Cancer Genetics?

Cancer Genetics has a market capitalization of $13.01 million and generates $7.30 million in revenue each year. Cancer Genetics employs 110 workers across the globe.

What is Cancer Genetics' official website?

The official website for Cancer Genetics is www.cancergenetics.com.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.